New FDA antipsychotic Warnings: "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding."
"Prescription Drugs Associated with Reports of Violence Towards Others, " identifies 31 drugs linked to 1,527 acts of violence…
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.”
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’…
The prescribed drugs transformed Kyle Warren from a rambunctious healthy child into a drooling, sedated, obese, “shell.”
The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research.
"Dr. Nemeroff has become the poster child for what’s wrong with academic medicine in our country." Dr. Thomas Insell, Director of the NIMH, quietly helped him get a prized position at the University of Miami.
"Her mother’s murder trial has been over for a couple of weeks now, but I’m still haunted by little Rebecca Riley."
In the first half of the twenty-first century, U.S. psychiatrists are prescribing the second generation neuroleptics—Zyprexa, Risperdal, Geodon, Seroquel, Abilfy—to coerce innocent children and the elderly into submission.
Sen. Grassley obtained documents confirming NAMI as a front group for pharma companies who underwrite ¾ of NAMI donations—in 2006 to 2008 that was a hefty $23 million.
Pfizer, the world’s largest drug manufacturer has the dubious distinction of being a corporate "repeat offender…"
At the July 30, 2009 FDA advisory committee hearing, the only formal presentations at the meeting were a summary of the safety and efficacy data by the sponsor.
